James Carroll

1.9k total citations
18 papers, 838 citations indexed

About

James Carroll is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, James Carroll has authored 18 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in James Carroll's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Genomics and Diagnostics (6 papers). James Carroll is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Genomics and Diagnostics (6 papers). James Carroll collaborates with scholars based in United States, Canada and France. James Carroll's co-authors include James A. Russell, James A. Russell, James A. Russell, Michelle Yik, Lisa Feldman Barrett, Jonathan W. Goldman, Edward B. Garon, Aaron Lisberg, Timothy J. Williamson and John Madrigal and has published in prestigious journals such as Journal of Personality and Social Psychology, Journal of Clinical Oncology and Psychological Bulletin.

In The Last Decade

James Carroll

18 papers receiving 788 citations

Peers

James Carroll

ECP

ONCOL

PRM

Heather Linz United States

Zhiguo Hu China

Karin M. Butler United States

Kathryn McCabe Australia

Maki Ikeda Japan

Yaniv Stein Israel

Maurizio Mauri Italy

Greg Shelley United States

Rinus G. Verdonschot Japan

Heather Linz United States

James Carroll

280 ×0.8

ECP

108 ×0.3

291 ×0.9

86 ×0.6

ONCOL

35 ×0.4

PRM

Citations per year, relative to James Carroll James Carroll (= 1×) peers Heather Linz

Countries citing papers authored by James Carroll

Since Specialization

Citations

This map shows the geographic impact of James Carroll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Carroll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Carroll more than expected).

Fields of papers citing papers by James Carroll

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Carroll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Carroll. The network helps show where James Carroll may publish in the future.

Co-authorship network of co-authors of James Carroll

This figure shows the co-authorship network connecting the top 25 collaborators of James Carroll. A scholar is included among the top collaborators of James Carroll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Carroll. James Carroll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Rochigneux, Philippe, Aaron Lisberg, Alejandro J. Garcia, et al.. (2022). Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. Clinical Cancer Research. 28(23). 5136–5148. 20 indexed citations

Vuppalapaty, Meghah, Corinne Renier, James Che, et al.. (2020). Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. Frontiers in Oncology. 10. 572895–572895. 43 indexed citations

Hu‐Lieskovan, Siwen, Aaron Lisberg, Jesse M. Zaretsky, et al.. (2019). Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(16). 5061–5068. 56 indexed citations

Lisberg, Aaron, Siwen Hu‐Lieskovan, Tristan Grogan, et al.. (2018). P2.09-05 Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001. Journal of Thoracic Oncology. 13(10). S761–S761. 2 indexed citations

Williamson, Timothy J., Edward B. Garon, Jenessa R. Shapiro, et al.. (2018). A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. Journal of Thoracic Oncology. 13(9). 1284–1293. 37 indexed citations

Lisberg, Aaron, Amy L. Cummings, Jonathan W. Goldman, et al.. (2018). A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.. Journal of Clinical Oncology. 36(15_suppl). 9014–9014. 5 indexed citations

Sollier‐Christen, Elodie, Meghah Vuppalapaty, James Che, et al.. (2018). Abstract 1598: EGFR mutational detection in vortex-enriched CTCs, ctDNA, and comparison to tumor tissue in non-small cell lung cancer (NSCLC) patients. Cancer Research. 78(13_Supplement). 1598–1598. 1 indexed citations

Lisberg, Aaron, John Horton, Jonathan W. Goldman, et al.. (2017). P3.02b-042 Reduction in Peripheral Blood Cytokine Levels Observed in EGFR Mutant (EGFRm) Patients Treated with Erlotinib. Journal of Thoracic Oncology. 12(1). S1212–S1213. 1 indexed citations

Lisberg, Aaron, D. Andrew Tucker, Jonathan W. Goldman, et al.. (2017). P3.02c-083 Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Journal of Thoracic Oncology. 12(1). S1328–S1328. 1 indexed citations

10.

Gaut, Daria, Myung‐Shin Sim, Brian R. Wolf, et al.. (2017). Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non–Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer. 19(1). e19–e28. 19 indexed citations

11.

Lisberg, Aaron, Krikor Bornazyan, John Madrigal, et al.. (2017). P2.07-038 Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA. Journal of Thoracic Oncology. 12(11). S2430–S2430. 1 indexed citations

12.

Lisberg, Aaron, J.S. Hunt, Nicholas Reese, et al.. (2017). MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC. Journal of Thoracic Oncology. 12(11). S1805–S1805. 4 indexed citations

13.

Goldman, Jonathan W., Manjima Dhar, James Che, et al.. (2015). Abstract B98: Serial evaluation of PD-L1 expression on circulating tumor cells (CTCs). Molecular Cancer Therapeutics. 14(12_Supplement_2). B98–B98. 1 indexed citations

14.

Russell, James A. & James Carroll. (1999). On the bipolarity of positive and negative affect.. Psychological Bulletin. 125(1). 3–30. 68 indexed citations

15.

Carroll, James, Michelle Yik, James A. Russell, & Lisa Feldman Barrett. (1999). On the Psychometric Principles of Affect. Review of General Psychology. 3(1). 14–22. 81 indexed citations

16.

Russell, James A. & James Carroll. (1999). The phoenix of bipolarity: Reply to Watson and Tellegen (1999).. Psychological Bulletin. 125(5). 611–617. 58 indexed citations

17.

Carroll, James & James A. Russell. (1997). Facial expressions in Hollywood's protrayal of emotion.. Journal of Personality and Social Psychology. 72(1). 164–176. 107 indexed citations

18.

Carroll, James & James A. Russell. (1996). Do facial expressions signal specific emotions? Judging emotion from the face in context.. Journal of Personality and Social Psychology. 70(2). 205–218. 333 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact